Kornimate/medical-research-clean huggingface dataset:
optimizing clinical screening and management of maternal mental health: predicting women at risk for perinatal depression

Conditions: Depression

Summary: the purpose of this study is to determine if medical, biological, psychological, and social risk factors can be used to develop algorithms that will predict perinatal depression (pnd). data capture will include baseline participant medical, psychological and family history, blood biomarkers, and psychosocial assessments.


Eligibility criteria:
inclusion criteria: * participants must be english-speaking and able to understand and follow clinician/researcher/provider recommendations * participants must be able to read and comprehend written communications (english) and physically able to complete electronic patient-reported outcome (epro) assessments * participants must have access to a personal smartphone or a computer and an active personal email address for which they are willing to use for data collection * each participant must sign an informed consent form (icf) indicating that she understands the purpose of and procedures required for this study and is willing to participate in and comply with all procedures in the study * participant must be willing and able to have blood draws and to complete the self-reported assessments via mobile electronic device during the study exclusion criteria: * participant is not english speaking * lifetime mood disorder other than major depressive disorder (mdd) (example \[e.g.\], bipolar i) or anxiety disorder * lifetime psychotic disorder (eg, schizophrenia, schizoaffective disorder) * lifetime alcohol or illicit substance dependence (moderate-severe) * current post-traumatic stress disorder (ptsd), significant alcohol or illicit drug use (ethanol \[etoh\]/nonprescription drug use) within 12 months greater than or equal to (\>=)occasional use
randomized controlled trial of project body neutrality

Conditions: Depression; Eating Disorders; Body Image

Summary: this study tests a single-session intervention (ssi) targeting risk factors for depression and eating disorders among sexual and gender minority (sgm) adolescents. youth ages 13-17 who identify as sexual or gender minorities will be randomized to the intervention condition (project body neutrality ssi) or a control (supportive therapy ssi). participants will complete questionnaires before the intervention, immediately after the intervention, and 3-months after completing the intervention so that the study team can investigate if project body neutrality leads to reductions in depression and eating disorder symptoms compared to the control.


Eligibility criteria:
inclusion criteria: * identify as a sexual or gender minority individual per self-report * 13-17 years old at the time of enrollment * english proficiency per self-report * report having body image concerns per self-report * score of ≥ 2 on the patient health questionnaire-2 (phq-2; kroenke et al., 2003), - indicating elevated depressive symptoms * did not participate in a past study involving project body neutrality per self-report * residing within the united states per ip address * passes comprehension of consent language assessment exclusion criteria: * fail to meet the above-listed inclusion criteria * exit the study prior to condition randomization * failure to pass the data integrity measures * duplicate responses from the same individual in baseline or follow-up surveys
platform therapeutic education in heart failure and coronary disease

Conditions: Heart Failure; Acute Coronary Syndrome; Coronary Bypass Graft Stenosis of Native Artery Graft

Summary: a first therapeutic education is given before patient's discharge at the hospital, then a dedicated nurse follows patients through the phone,regularly according to patients' needs, continues to give advise on risk factors, information on medication and alert symptoms and therapeutic education.

patients are assigned to an arm accordingly to their needs: class 1 with light therapeutic education, class 2 with moderate education, class 3 with heavy education. assignement is based on the first education diagnosis during hospitalization time. quality of life and patient's knowledge are regularly evaluated through questionnaires

Eligibility criteria:
inclusion criteria: * hospitalization for acute coronary syndrome (st-segment elevation myocardial infarction ,no st-segment elevation myocardial infarction st , unstable angina) * hospitalization for heart failure * acute coronary syndrome \< 3 months * heart failure \< 3 months * coronary by-pass surgery \< 3 months exclusion criteria: * complicated acute coronary syndrome (ventricular arrhythmia, heart failure, mechanical complications, cardiogenic shock) * valvular cardiac pathology * obstructive cardiomyopathy * planned cardiac transplantation * severe neurological or psychiatric troubles * loss of autonomy * other (refusal, language, nursing house, way of life not compatible with follow up, refusal of telephonic contacts)

Keywords: education risk factors quality of life coronary disease telephone follow up dedicated nurse
early versus late extubation in myasthenia gravis patients

Conditions: Myasthenia Gravis Associated With Thymoma

Summary: myasthenia gravis (mg) is an autoimmune disease characterized by varying degrees of muscle weakness and fatigability worsened with exertion and relieved with rest。thymectomy plays an important role in the management of these patients because a consistent association between myasthenic and thymic pathology has been recognized.the need for prolonged mechanical ventilation in these patients after thymectomy is determined by their preoperative condition and various perioperative risk factors. leventhal et al proposed a preoperative scoring system to predict the need for postoperative mechanical ventilation in myasthenic patients undergoing thymectomy based on the following 4 criteria: duration of mg, chronic respiratory disease, dose of pyridostigmine, and vital capacity. however, some investigators discovered that the leventhal criteria may not be the sole benchmark and that other criteria such as severity of myasthenia,history of myasthenic crisis, and presence of thymoma may be more important in predicting the necessity for prolonged mechanical ventilation after thymectomy. naguib et al described multivariate determinants of the need for postoperative ventilation after thymectomy in mg patients predominantly on the basis of pulmonary function tests. in addition, the prevalence and presentation of mg may be variable among different ethnic groups. however, there are very few large studies investigating the determinants of prolonged mechanical ventilation after thymectomy. the authors describe the parameters associated with prolonged mechanical ventilation after trans-sternal thymectomy at their institution.

perioperative variables collected from the patient records were demographic data, duration of the disease,severity of the disease based on osserman's classification, antiacetylcholine receptor (achr) antibody positivity, preoperative drug therapy, history of preoperative myasthenic crisis, technique of anesthesia, drugs used for anesthesia, perioperative complications, and duration of postoperative mechanical ventilation. even though the mg classification by the myasthenia gravis foundation of america is widely accepted,disease severity was graded according to the osserman and genkins classification preoperatively as per the authors' institutional protocol.

Eligibility criteria:
inclusion criteria: * myasthenia gravis patients after thymectomy exclusion criteria: * not extubation
collaborative care in posttraumatic epilepsy

Conditions: Epilepsy, Post-Traumatic

Summary: the purpose of this research is to evaluate a 6 month change in quality of life in subjects who receive collaborative care calls compared to those subjects who receive usual neurology care. this is a 2-site trial comparing a 24 week neurology-based collaborative care program to usual neurology care among a total of 60 adults with post-traumatic epilepsy.

the study will compare collaborative care versus usual care among n=60 adults with post-traumatic epilepsy and anxiety and/or depression symptoms in veterans administration (n=20) and civilian university (n=40) settings at the salisbury va and atrium health neurology. this single-blind study will evaluate effectiveness and implementation of a remotely-delivered, 24-week team-delivered collaborative care intervention, with features adapted from va primary care mental health integration and whole health, as well as an existing family medicine collaborative care program at ahwfb.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures * diagnosis of post-traumatic epilepsy, defined by the following: 1. epilepsy diagnosis based on neurology clinician impression of diagnosis or electroencephalogram (eeg) findings (eeg findings: presence of interictal epileptiform discharges on eeg or ictal eeg recording of seizure definitively documenting epilepsy diagnosis) 2. history of at least mild traumatic brain injury based on the mirecc (mental illness research, education, and clinical center) tbi (traumatic brain injury) screening instrument or verified tbi history based on mirecc research database 3. tbi pre-dated onset of epilepsy (ninds post-traumatic epilepsy screening form) * anxiety or depression symptoms--generalized anxiety disorder scale (gad-7) ≥8 or neurological disorders depression inventory for epilepsy (nddi-e) \>13 * receiving clinical neurological care at one of the study sites exclusion criteria: * active ongoing treatment by a psychiatrist without the potential to benefit from additional collaborative care for anxiety or depression in the judgement of the investigators * active suicidal ideation * history of past suicide attempt * unstable drug or alcohol abuse * unstable or progressive comorbid medical condition * current participation in another treatment or intervention study * cognitive limitations precluding completion of anxiety and depression self-report instruments on paper, electronically, or by interview.

Keywords: epilepsy neurological care collaborative care anxiety depression
insomnia treatment and problems (the itap study)

Conditions: Insomnia; Alcohol; Harmful Use

Summary: this project aims to evaluate the efficacy of insomnia treatment in improving insomnia symptoms and alcohol-related problems among heavy-drinking young adults.

heavy alcohol use is prevalent among young adults and results in significant physical and psychological burden. despite wide implementation of alcohol risk reduction efforts on college campuses, rates of heavy alcohol consumption remain high, with 35% of students reporting consumption of 5+ drinks on the same occasion in the past 2 weeks. thus, additional strategies are needed to reduce the burden of heavy alcohol use among college students. more than half of heavy-drinking college students report symptoms of insomnia. in turn, insomnia symptoms have been associated with increased risk of alcohol-related problems. the proposed project aims to reduce the burden of heavy alcohol use on college campuses by examining the efficacy of cognitive behavioral therapy for insomnia (cbt-i) in reducing alcohol use and related problems among heavy-drinking college students. twenty seven young adults who indicate risk for problem drinking and meet dsm-5 criteria for insomnia disorder will participate in a 5-week pilot trial. participants will complete five individual sessions of cbt-i. outcomes will be assessed at the end of the active intervention period (6 weeks) and 1 month post-intervention. outcomes of interest include insomnia severity, total wake time, sleep quality, drinking quantity, and alcohol-related consequences. the proposed research aims to reduce the harms associated with heavy alcohol use among young adults by improving the availability of efficacious treatment. it will impact understanding of the benefits of cbt-i, and it is innovative because it evaluates improvement in insomnia as a mechanism for improvements in alcohol use disorder (aud). this research is consistent with the national institute on alcohol abuse and alcoholism's initiative to evaluate and promote interventions that prevent the progression of aud in diverse populations. it will enhance the stature of the university by improving our ability to compete successfully for federal funding to conduct high-quality research.

Eligibility criteria:
inclusion criteria: * age 18-30 years * heavy episodic drinking, defined as 1 heavy drinking episode (4/5+ drinks for women/men) in the past 30 days on the timeline followback * dsm-5 criteria for insomnia, with "daytime impairment" operationalized as isi scores =\>10 exclusion criteria: * unable to provide informed consent * new sleep medication in the past 6 weeks * contraindications for cbt-i (mania or seizure disorder) * severe psychiatric disorder that requires clinical attention (ptsd, major depression) * current treatment for insomnia or alcohol use

Keywords: alcohol drinking sleep insomnia young adult
evaluate safety and efficacy of alveo hp balloon dilatation catheter for balloon dilatation of coronary artery stenosis

Conditions: Coronary Artery Disease

Summary: this is a prospective, multi-center, single-group study aims to evaluate the safety and efficacy of alveo hp balloon dilatation catheter for balloon dilatation of coronary artery stenosis. pre-dilation with alveo balloon dilatation catheter followed by conventional pci, and follow-up will be carried out. during the trial, the enrollment, treatment and follow-up of the subjects will be recorded, and the safety and efficacy of the investigational device will be evaluated.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old, gender is not limited; 2. patients with symptomatic ischemic heart disease who are suitable for percutaneous coronary intervention (pci); 3. patients with target lesion diameter stenosis ≥ 70% (visually) or chronic total occlusion (cto) who needed balloon dilatation catheter pre-dilatation; 4. patients or their guardians who can understand the purpose of the trial, voluntarily participate and sign the written informed consent, and can accept follow-up; exclusion criteria: 1. patients with clinical symptoms consistent with st-segment elevation myocardial infarction or/and ecg changes within 12 hours prior to the procedure; 2. patients who are known to be intolerant to antiplatelet drugs or allergic to contrast media; 3. patients with in-stent restenosis; 4. patients with unprotected left main coronary artery disease; 5. patients who plan to treat 3 or more lesions at the same time; 6. patients with severe calcified lesions; 7. patients in whom the guidewire cannot pass through the lesion; 8. women who are pregnant or lactating; 9. patients who are participating in the clinical trial of other drugs or medical devices; 10. other patients considered by the investigator to be unsuitable for this trial.
study of autologous immune killer cells in patients with late stage hepatocellular carcinoma or lung cancer

Conditions: NSCLC Stage IIIB; NSCLC Stage IV; Hepatocellular Carcinoma by BCLC Stage; Lung Cancer; Liver Cancer

Summary: this is a phase i clinical study. blood is drawn from the patient and brought to our laboratory for isolation of immune cells. these immune cells are then proliferated over a two week period and used to produce our patented product ikc (immune killer cells). the ikc will then infused back into the patient to treat the cancer. each patient will receive a total of six infusions.

this is a phase i clinical study. blood is drawn from the patient and brought to our laboratory for isolation of immune cells. these immune cells are then proliferated over a two week period and used to produce the patented product ikc (immune killer cells). the ikc will then infused back into the patient to treat the cancer. each patient will receive a total of six infusions. for each indication (cancer of the lung or liver) 10 patients are anticipated to be recruited, making a total of 20 subjects. all subjects will receive treatment as this is a single-arm study.

Eligibility criteria:
inclusion criteria: 1. subjects had voluntarily given written informed consent 2. subjects had ct scan on lung or liver tumors within the past 4 weeks of the screening visit 3. subjects who were histologically or pathologically confirmed with locally advanced or metastatic lung cancer or hcc 4. subjects who did not have valid therapy, ever failed with other therapy, or refused or were not appropriate for other therapies for lung cancer or hcc 5. subjects' ecog performance status ≤ 2 6. subjects with life expectancy ≥ 3 months exclusion criteria: 1. subjects with medical history of gout 2. subjects who had participated other clinical trials within 4 weeks before the screening visit 3. subjects with positive result of hiv or htlv test within 4 weeks before the screening visit 4. subjects with clinically significant diseases other than cancer 5. subjects with myocardial infraction, stroke, or congestive heart failure within 3 months before the screening visit 6. female subjects who were pregnant or lactating or women of child-bearing potential but unable to take adequate contraception 7. subjects with history of alcohol, drug or other substance abuse 8. subjects with disease of bacteremia
neoadjuvant sequential therapy in locally advanced mid/low rectal cancer

Conditions: Rectal Cancer

Summary: compared curative effect，safety and compliance between concurrent chemoradiotherapy and chemo-chemoradio-chemo sequential therapy in locally advanced mid/low rectal cancer.

the patients were divided into two arms according to the defined conditions (pathology rectal adenocarcinoma；distal distance of tumor from anal verge \< 10cm；tnm staging t3-4n0-2；no distant metastasis；karnofsky score≥70) in this prospective, single center, open, non randomized trail (arm a:concurrent chemoradiotherapy, arm b:sequential therapy). regimens:arm a:50gy,2gy/day per time, 5 days a week, for 5 weeks. +capecitabine 850mg/m2 bid on the day accept radiotherapy. rest for 8 weeks. arm b: xelox 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1, capecitabine 1000 mg/m2 bid day 1-14, repeat every 3 weeks ) → 50gy,2gy/day per time, 5 days a week, for 5 weeks.+capecitabine 850mg/m2 bid on the day accept radiotherapy → xelox 1 cycle. rest for 2 weeks. evaluate pre chemotherapy, pre radiotherapy and pre surgery individually. surgeries followed tme(total mesorectal excision) and panp(pelvic autonomic nerve preservation) for patients in both arms. take pathological evaluation of tumors. take xelox therapy till 6-8 cycles(pre and after surgery total). follow up according the schedule.

Eligibility criteria:
inclusion criteria: * pathology rectal adenocarcinoma * distal distance of tumor from anal verge \< 10cm * tnm staging t3-4n0-2(mri) * no distant metastasis * karnofsky score≥70 * female patients need contraception during the test * postmenopausal women for at least 12 months, expect pregnancy possibility * patients did not receive chemotherapy, radiotherapy in any form before * no other severe related diseases (such as other tumor, severe cardiac and central nervous system diseases, etc.) exclusion criteria: * be treated by radiotherapy, chemotherapy or tumor biological therapy before * received immunosuppressive therapy (including corticosteroids) * participated in other clinical trial(s) in 1 month * with malignant tumor of colon * peripheral neuropathy (who i level and above) * neurological or psychiatric abnormalities affecting cognition , including central nervous system metastasis * severe allergies or allergic history * severe pulmonary or heart disease * pregnant or lactation or refuse contraception during the test * suffering other malignant tumors in past

Keywords: rectal cancer concurrent chemoradiotherapy sequential therapy
clinical application of ctdna in operable breast cancer patients

Conditions: Breast Cancer

Summary: our study aims to evaluate the possibility of clinical application of ctdna detection in samples or peripheral blood of breast cancer patients, so as to act as the new techniques or indicators of early diagnosis, therapy efficiency, or postoperative surveillance of breast cancer.


Eligibility criteria:
inclusion criteria: 1. written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures. 2. age of at least 18 and at most 70 years. 3. performance status (karnofsky-index) \>80%. 4. chemotherapy is necessary before or after surgery. 5. no clinical evidence of local recurrence or distant metastases. 6. complete staging work-up within 3 months prior to registration. all patients must have (bilateral) mammography or breast mri, chest x-ray; other tests may be performed as clinically indicated. 7. life expectancy of at least 2 years, disregarding the diagnosis of cancer. 8. adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution. 9. patients must be available for and compliant to treatment and follow-up. 10. patients registered on this trial must be treated and followed up at the participating center. exclusion criteria: 1. known hypersensitivity reaction to the investigational compounds or incorporated substances. 2. local recurrence and/or metastasis of breast cancer. 3. no need of chemotherapy. 4. pregnant or lactating patients. patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration. prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix) 5. any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled high risk arrhythmias 6. other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study. 7. concurrent treatment with other experimental drugs or any other anti-cancer therapy. 8. males.

Keywords: breast cancer ctdna neoadjuvant chemotherapy adjuvant chemotherapy